e-Therapeutics PLC - Oxford, England-based computer-based drug discovery company - Increases loss after investing more in research & development. Pretax loss for the year ended January 31 widens to £9.5 million from £4.5 million a year ago. Revenue grows to £477,000 from £317,000.

The company invests £6.1 million in research & development, sharply up from £2.7 million a year ago. Significant progress has been made in developing an RNAi therapeutics platform, firm explains. Administrative expenses widen to £3.9 million from £2.1 million.

Citing its budget, e-Therapeutics says ‘we have sufficient funds to continue in operational existence for at least 12 months from the signing of these financial statements.’ Adds that it could scale back discretionary spend if appropriate.

Current stock price: 25.20 pence, down 6.3% on Wednesday

12-month change: down 13%

Copyright 2022 Alliance News Limited. All Rights Reserved.